PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.

Detalles Bibliográficos
Autores principales: Naylor, G. U., Mant, S., Bedford, C., Turner, D., Furtado, M., Lewis, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431599/
http://dx.doi.org/10.1097/01.HS9.0000851172.77306.8c
_version_ 1784780099215687680
author Naylor, G. U.
Mant, S.
Bedford, C.
Turner, D.
Furtado, M.
Lewis, D.
author_facet Naylor, G. U.
Mant, S.
Bedford, C.
Turner, D.
Furtado, M.
Lewis, D.
author_sort Naylor, G. U.
collection PubMed
description
format Online
Article
Text
id pubmed-9431599
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94315992022-08-31 PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES. Naylor, G. U. Mant, S. Bedford, C. Turner, D. Furtado, M. Lewis, D. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431599/ http://dx.doi.org/10.1097/01.HS9.0000851172.77306.8c Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Naylor, G. U.
Mant, S.
Bedford, C.
Turner, D.
Furtado, M.
Lewis, D.
PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
title PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
title_full PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
title_fullStr PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
title_full_unstemmed PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
title_short PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
title_sort pb2085: upfront treatment of mantle cell lymphoma (mcl) with r-hdac (rituximab-high dose cytarabine + dexamethasone) in young, high risk patients is well tolerated and leads to durable responses.
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431599/
http://dx.doi.org/10.1097/01.HS9.0000851172.77306.8c
work_keys_str_mv AT naylorgu pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses
AT mants pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses
AT bedfordc pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses
AT turnerd pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses
AT furtadom pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses
AT lewisd pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses

Ejemplares similares